“The consumer space increasingly active and of course the healthcare space – healthcare broadly defined – pharmaceutical, equipment, services, the whole healthcare space undergoing a lot of scrutiny in terms of deals and just started to see the beginning of a lot of activity in chemicals,” Studzinski added.

Deals in the pharmaceutical, medical and biotech space is also at an all-time year-to-date high.

Additionally, the PowerShares Dynamic Biotechnology & Genome Portfolio (NYSEArca: PBE), BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC) and ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) have all benefited from their tilt toward smaller biotech names that are developing new targeted treatments. [ETFs for the Next Biotech Takeover Targets]

For more information on the market sectors, visit our sector ETFs category.

Max Chen contributed to this article.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.